Angiology · 2001 · 22 citations · 9 references
MedicineHealth PolicyPharmacotherapyClinical MedicineGeneral Internal MedicineHealth InsuranceChronic DiseaseDeep Vein ThrombosisMedication Coverage PolicyThrombosisThrombosis ManagementVenous DiseaseCoveragePublic-private Insurance SchemesReasonable Health Insurance CoverageRepresentative SamplesSocial Utility Functions
A recent (1999) Sofres survey of representative samples of the adult French population aged 15 and over showed that almost half this population suffered from lower limb venous complaints and that 43% of them were untreated. Of those treated, 24.2% received venotropics, including 21.5% by prescription, while 6.0% practiced self-medication. Venous disease sufferers form a relatively underprivileged sector of the population in terms not only of age, income, work and living conditions, but also of general health and medical history. Despite its clinical efficacy and potential social utility, venotropic treatment is possible only if backed by adequate state health insurance coverage supplemented by mutual and private insurance schemes. Any restriction to such coverage will only decrease access to prescription venotropics.
9
The economic cost of obesity: the French situation.
Émile Lévy, Pierre Lévy, C. Le Pen et al. · PubMed · 1995 · 157 citations
Venous Insufficiency in Male Workers with a Standing Profession
R. M. A. Krijnen, E. M. de Boer, H. J. Adèr et al. · Dermatology · 2009 · 86 citations
Epidemiology of Chronic Venous Insufficiency
Guy De Backer, Guy De Backer · Angiology · 1997 · 42 citations